13F Holdings
中文EN

XFOR X4 Pharmaceuticals, Inc

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1501697 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY73.7%
TTM net income YoY15.3%
TTM EPS YoY106.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin68.8%
Operating margin-812.0%
Net margin-813.3%
FCF margin—
EBITDA margin-794.1%

Returns

ROE-80.3%
ROA-40.7%
ROIC (approx.)-134.7%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets40.1%
Debt / equity0.54x
Current ratio13.22x
Interest coverage-9.26x

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-2.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$6.50M$2.60M$0$0$0
Cost of revenue$5.76M$797,000$0$0—
Gross profit$743,000$1.80M$0$0—
R&D expense$72.72M$81.64M$72.02M$61.06M$50.65M
SG&A expense$43.52M$61.52M$35.51M$27.02M$24.70M
Operating income-$86.88M-$36.40M-$107.52M-$87.57M-$85.11M
Interest expense$8.88M$8.77M$5.78M$3.99M$3.64M
Pretax income-$79.16M-$37.14M-$101.09M-$93.84M-$88.68M
Income tax$41,000$310,000$78,000$28,000$17,000
Net income-$79.20M-$37.45M-$101.17M-$93.87M-$88.70M
EBITDA-$85.61M-$35.60M-$107.10M-$87.06M-$84.61M
EPS (basic)-1.87-5.59-17.07-1.52-3.99
EPS (diluted)-1.87-5.59-17.07-1.52-3.99
Weighted avg. shares (diluted)42.29M6.70M5.93M63.53M25.75M
Balance sheet
Cash & equivalents$217.05M$56.48M$100.25M$123.03M$83.11M
Receivables$573,000$1.07M$0——
Inventory$4.48M$2.82M$0——
Current assets$261.58M$112.17M$122.08M$128.68M$87.88M
PP&E, net$182,000$776,000$745,000$1.10M$1.51M
Goodwill$17.35M$17.35M$17.35M$17.35M$17.35M
Intangibles$9.25M$10.00M$0——
Total assets$290.46M$146.45M$147.26M$155.59M$117.18M
Current liabilities$25.76M$32.88M$22.86M$22.32M$14.02M
Short-term debt——$0$1.31M$795,000
Long-term debt$75.00M$75.00M$55.00M$32.30M$33.14M
Total debt$75.00M$75.00M$55.00M$33.62M$33.93M
Total liabilities$104.17M$124.30M$96.16M$81.53M$52.76M
Shareholders' equity$186.29M$22.15M$51.10M$74.05M$64.41M
Net debt-$142.05M$18.52M-$45.25M-$89.41M-$49.17M
Shares outstanding90.91M5.70M167.43M121.67M28.13M
Cash flow statement
Operating cash flow-$85.62M-$130.90M-$96.51M-$77.10M-$70.91M
Capital expenditure$0$326,000$60,000$103,000$615,000
Free cash flow-$85.62M-$131.23M-$96.57M-$77.20M-$71.52M
Investing cash flow$8.15M$66.99M-$14.88M-$103,000-$615,000
Financing cash flow$238.63M$20.29M$88.52M$117.23M$74.25M
Depreciation & amortization$1.28M$796,000$419,000$513,000$499,000
Stock-based compensation$4.30M$8.20M$8.69M$5.20M$6.18M
Share buybacks——$0$0$2.00M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.